DOI: 10.18413/2658-6533-2023-9-3-0-1

The role of DNA methylation in lung cancer (review)

Aigul R. Nizamova
Galiya F. Gimalova
Elza K. Khusnutdinova

Background: Lung cancer has been a difficult-to-treat disease for decades, despite the efforts of oncologists and pharmaceutical companies. One of the reasons for this is the heterogeneity of the genetic profiles of tumors. In recent years, the interest of researchers has been attracted by epigenetic changes within the tumor, in particular, DNA methylation. This paper reviews the distinctive features of the main subtypes of lung cancer, discusses the role of DNA methylation in non-small cell and small cell lung cancer, as well as its role in tumor response to therapy. The aim of the study: To summarize the results of DNA methylation analysis in lung cancer for a better understanding of the biological nature of the oncogenesis of this disease in order to use the identified biomarkers for early diagnosis of pathology and assessing the patient's prognosis. Materials and methods: The literature analysis was carried out in the PubMed, Google Scholar databases for the period from 1995 to 2022. Results: It was shown that the pattern of DNA methylation changes under the influence of smoking, and the changes persist even after smoking is stopped. Aberrantly methylated genes have been identified that can serve as biomarkers for lung cancer screening at early or late stages. These genes include: H19, HOXA3/HOXA4, RUNX3, BRICD5, PLXNB2, RP13, DIABLO, RASSF1A, SHOX2, EZH2, NEUROD1 and others. Moreover, it has been found that the methylation status of certain regions of DNA in small cell lung cancer correlates with tumor response to chemotherapy and radiotherapy. Conclusion: Changes in the DNA methylation profiles of individuals can serve as markers for early diagnosis of the disease, and can be used as targets for therapeutic intervention, as well as to assess the patient's prognosis.

Keywords: lung cancer, epigenetics, DNA methylation, CpG-islands, smoking.

Number of views: 422 (view statistics)

Количество скачиваний: 629

Full text (HTML)Full text (PDF)To articles list

Information for citation:

Nizamova AR, Gimalova GF, Khusnutdinova EK. The role of DNA methylation in lung cancer (review). Research Results in Biomedicine. 2023;9(3):293-311. Russian. DOI: 10.18413/2658-6533-2023-9-3-0-1

User comments
Reference lists

While nobody left any comments to this publication.
You can be first.

GLOBOCAN [Internet] [cited 2022 July 7]. Available from: https://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf
Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543-50. DOI: https://doi.org/10.1038/nature13385
Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489(7417):519-25. DOI: https://doi.org/10.1038/nature11404
Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446-454. DOI: https://doi.org/10.1038/nature25183
Marino FZ, Bianco R, Accardo M, et al. Molecular heterogeneity in lung cancer: from mechanisms of origin to clinical implications. International Journal of Medical Sciences. 2019;16(7):981-989. DOI: https://doi.org/10.7150/ijms.34739
Sabari JK, Lok BH, Laird JH, et al. Unravelling the biology of SCLC: implications for therapy. Nature Reviews Clinical Oncology. 2017;14(9):549-561. DOI: https://doi.org/10.1038/nrclinonc.2017.71
Rudin CM, Brambilla E, Faivre-Finn C, et al. Small-cell lung cancer. Nature Reviews Disease Primers. 2021;7:3. DOI: https://doi.org/10.1038/s41572-020-00235-0
George J, Lim JS, Jang SJ, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015;524(7563):47-53. DOI: https://doi.org/10.1038/nature14664
Peifer M, Fernández-Cuesta L, Sos ML, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nature Genetics. 2012;44(10):1104-1110. DOI: https://doi.org/10.1038/ng.2396
Rudin CM, Durinck S, Stawiski EW, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nature Genetics. 2012;44(10):1111-1116. DOI: https://doi.org/10.1038/ng.2405
Augert A, Zhang Q, Bates B, et al. Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance). Journal of Thoracic Oncology. 2017;12(4):704-713. DOI: https://doi.org/10.1016/j.jtho.2016.12.011
Kim KB, Dunn CT, Park KS. Recent progress in mapping the emerging landscape of the small-cell lung cancer genome. Experimental and Molecular Medicine. 2019;51(12):1-13. DOI: https://doi.org/10.1038/s12276-019-0349-5
Rudin CM, Poirier JT, Byers LA, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nature Reviews Cancer. 2019;19(5):289-297. DOI: https://doi.org/10.1038/s41568-019-0133-9
Baine MK, Hsieh MS, Lai WV, et al. SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization. Journal of Thoracic Oncology. 2020;15(12):1823-1835. DOI: https://doi.org/10.1016/j.jtho.2020.09.009
Gay CM, Stewart CA, Park EM, et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021;39(3):346-360.e7. DOI: https://doi.org/10.1016/j.ccell.2020.12.014
Heyn H, Esteller M. DNA methylation profiling in the clinic: applications and challenges. Nature Reviews Genetics. 2012;13(10):679-692. DOI: https://doi.org/10.1038/nrg3270
Timp W, Feinberg AP. Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nature Reviews Cancer. 2013;13(7):497-510. DOI: https://doi.org/10.1038/nrc3486
Abu-Remaileh M, Bender S, Raddatz G, et al. Chronic inflammation induces a novel epigenetic program that is conserved in intestinal adenomas and in colorectal cancer. Cancer Research. 2015;75(10):2120-2130. DOI: https://doi.org/10.1158/0008-5472.CAN-14-3295
Laird PW. The power and the promise of DNA methylation markers. Nature Reviews Cancer. 2003;3(4):253-266. DOI: https://doi.org/10.1038/nrc1045
Fasanelli F, Baglietto L, Ponzi E, et al. Hypomethylation of smoking-related genes is associated with future lung cancer in four prospective cohorts. Nature Communications. 2015;6:10192. DOI: https://doi.org/10.1038/ncomms10192
Zhang Y, Elgizouli M, Schöttker B, et al. Smoking-associated DNA methylation markers predict lung cancer incidence. Clinical Epigenetics. 2016;8:127. DOI: https://doi.org/10.1186/s13148-016-0292-4
Baglietto L, Ponzi E, Haycock P, et al. DNA methylation changes measured in pre-diagnostic peripheral blood samples are associated with smoking and lung cancer risk. International Journal of Cancer. 2017;140(1):50-61. DOI: https://doi.org/10.1002/ijc.30431
Joehanes R, Just AC, Marioni RE, et al. Epigenetic Signatures of Cigarette Smoking. Circulation: Cardiovascular Genetics. 2016;9(5):436-447. DOI: https://doi.org/10.1161/CIRCGENETICS.116.001506
Sandanger TM, Nøst TH, Guida F, et al. DNA methylation and associated gene expression in blood prior to lung cancer diagnosis in the Norwegian Women and Cancer cohort. Scientific Reports. 2018;8(1):16714. DOI: https://doi.org/10.1038/s41598-018-34334-6
Battram T, Richmond RC, Baglietto L, et al. Appraising the causal relevance of DNA methylation for risk of lung cancer. International Journal of Epidemiology. 2019;48(5):1493-1504. DOI: https://doi.org/10.1093/ije/dyz190
Fewell Z, Davey Smith G, Sterne JA. The impact of residual and unmeasured confounding in epidemiologic studies: a simulation study. American Journal of Epidemiology. 2007;166(6):646-655. DOI: https://doi.org/10.1093/aje/kwm165
Munafò MR, Timofeeva MN, Morris RW, et al. Association between genetic variants on chromosome 15q25 locus and objective measures of tobacco exposure. Journal of the National Cancer Institute. 2012;104(10):740-748. DOI: https://doi.org/10.1093/jnci/djs191
Zhang Y, Breitling LP, Balavarca Y, et al. Comparison and combination of blood DNA methylation at smoking-associated genes and at lung cancer-related genes in prediction of lung cancer mortality. International Journal of Cancer. 2016;139(11):2482-92. DOI: https://doi.org/10.1002/ijc.30374
Zhang X, Gao L, Liu ZP, et al. Uncovering Driver DNA Methylation Events in Nonsmoking Early Stage Lung Adenocarcinoma. BioMed Research International. 2016;2016:2090286. DOI: https://doi.org/10.1155/2016/2090286
Zhao N, Ruan M, Koestler DC, et al. Epigenome-wide scan identifies differentially methylated regions for lung cancer using pre-diagnostic peripheral blood. Epigenetics. 2022;17(4):460-472. DOI: https://doi.org/10.1080/15592294.2021.1923615
Sato K, Tomizawa Y, Iijima H, et al. Epigenetic inactivation of the RUNX3 gene in lung cancer. Oncology Reports. 2006;15(1):129-35. DOI: https://doi.org/10.3892/or.15.1.129
Huang Z, Lei W, Hu HB, et al. H19 promotes non-small-cell lung cancer (NSCLC) development through STAT3 signaling via sponging miR-17. Journal of Cellular Physiology. 2018;233(10):6768-6776. DOI: https://doi.org/10.1002/jcp.26530
Liu H, Zhao H. Prognosis related miRNAs, DNA methylation, and epigenetic interactions in lung adenocarcinoma. Neoplasma. 2019;66(3):487-493. DOI: https://doi.org/10.4149/neo_2018_181029N805
Gan BL, He RQ, Zhang Y, et al. Downregulation of HOXA3 in lung adenocarcinoma and its relevant molecular mechanism analysed by RT-qPCR, TCGA and in silico analysis. International Journal of Oncology. 2018;53(4):1557-1579. DOI: https://doi.org/10.3892/ijo.2018.4508
Daugaard I, Dominguez D, Kjeldsen TE, et al. Identification and validation of candidate epigenetic biomarkers in lung adenocarcinoma. Scientific Reports. 2016;6:35807. DOI: https://doi.org/10.1038/srep35807
Yanagawa N, Tamura G, Oizumi H, et al. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers. Lung Cancer. 2007;58(1):131-138. DOI: https://doi.org/10.1016/j.lungcan.2007.05.011
Mizutani Y, Nakanishi H, Yamamoto K, et al. Downregulation of Smac/DIABLO expression in renal cell carcinoma and its prognostic significance. Journal of Clinical Oncology. 2005;23(3):448-454. DOI: https://doi.org/10.1200/JCO.2005.02.191
Paul A, Krelin Y, Arif T, et al. A New Role for the Mitochondrial Pro-apoptotic Protein SMAC/Diablo in Phospholipid Synthesis Associated with Tumorigenesis. Molecular Therapy. 2018;26(3):680-694. DOI: https://doi.org/10.1016/j.ymthe.2017.12.020
Anisowicz A, Huang H, Braunschweiger KI, et al. A high-throughput and sensitive method to measure global DNA methylation: application in lung cancer. BMC Cancer. 2008;8:222. DOI: https://doi.org/10.1186/1471-2407-8-222
Langevin SM, Kratzke RA, Kelsey KT. Epigenetics of lung cancer. Translational Research. 2015;165(1):74-90. DOI: https://doi.org/10.1016/j.trsl.2014.03.001
Kondo M, Suzuki H, Ueda R, et al. Frequent loss of imprinting of the H19 gene is often associated with its overexpression in human lung cancers. Oncogene. 1995;10(6):1193-1198.
Niklinska W, Naumnik W, Sulewska A, et al. Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC). Folia Histochemica et Cytobiologica. 2009;47(2):275-80. DOI: https://doi.org/10.2478/v10042-009-0091-2
Feng H, Zhang Z, Qing X, et al. Promoter methylation of APC and RAR-β genes as prognostic markers in non-small cell lung cancer (NSCLC). Experimental and Molecular Pathology. 2016;100(1):109-113. DOI: https://doi.org/10.1016/j.yexmp.2015.12.005
Duruisseaux M, Esteller M. Lung cancer epigenetics: From knowledge to applications. Seminars in Cancer Biology. 2018;51:116-128. DOI: https://doi.org/10.1016/j.semcancer.2017.09.005
Malpeli G, Innamorati G, Decimo I, et al. Methylation Dynamics of RASSF1A and Its Impact on Cancer. Cancers. 2019;11(7):959. DOI: https://doi.org/10.3390/cancers11070959
Marchini A, Ogata T, Rappold GA. A Track Record on SHOX: From Basic Research to Complex Models and Therapy. Endocrine Reviews. 2016;37(4):417-448. DOI: https://doi.org/10.1210/er.2016-1036
Yi J, Jin L, Chen J, et al. MiR-375 suppresses invasion and metastasis by direct targeting of SHOX2 in esophageal squamous cell carcinoma. Acta Biochimica et Biophysica Sinica. 2017;49(2):159-169. DOI: https://doi.org/10.1093/abbs/gmw131
Peng X, Liu X, Xu L, et al. The mSHOX2 is capable of assessing the therapeutic effect and predicting the prognosis of stage IV lung cancer. Journal of Thoracic Disease. 2019;11(6):2458-2469. DOI: https://doi.org/10.21037/jtd.2019.05.81
Kneip C, Schmidt B, Seegebarth A, et al. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma. Journal of Thoracic Oncology. 2011;6(10):1632-1638. DOI: https://doi.org/10.1097/JTO.0b013e318220ef9a
Darwiche K, Zarogoulidis P, Baehner K, et al. Assessment of SHOX2 methylation in EBUS-TBNA specimen improves accuracy in lung cancer staging. Annals of Oncology. 2013;24(11):2866-2870. DOI: https://doi.org/10.1093/annonc/mdt365
Zhang C, Yu W, Wang L, et al. DNA Methylation Analysis of the SHOX2 and RASSF1A Panel in Bronchoalveolar Lavage Fluid for Lung Cancer Diagnosis. Journal of Cancer. 2017;8(17):3585-3591. DOI: https://doi.org/10.7150/jca.21368
Ooki A, Maleki Z, Tsay JJ, et al. A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non-Small Cell Lung Cancer and Serum DNA. Clinical Cancer Research. 2017;23(22):7141-7152. DOI: https://doi.org/10.1158/1078-0432.CCR-17-1222
Ren M, Wang C, Sheng D, et al. Methylation analysis of SHOX2 and RASSF1A in bronchoalveolar lavage fluid for early lung cancer diagnosis. Annals of Diagnostic Pathology. 2017;27:57-61. DOI: https://doi.org/10.1016/j.anndiagpath.2017.01.007
Alanazi IO, AlYahya SA, Ebrahimie E, et al. Computational systems biology analysis of biomarkers in lung cancer; unravelling genomic regions which frequently encode biomarkers, enriched pathways, and new candidates. Gene. 2018;659:29-36. DOI: https://doi.org/10.1016/j.gene.2018.03.038
Li N, Zeng Y, Huang J. Signaling pathways and clinical application of RASSF1A and SHOX2 in lung cancer. Journal of Cancer Research and Clinical Oncology. 2020;146(6):1379-1393. DOI: https://doi.org/10.1007/s00432-020-03188-9
Kalari S, Jung M, Kernstine KH, et al. The DNA methylation landscape of small cell lung cancer suggests a differentiation defect of neuroendocrine cells. Oncogene. 2013;32(30):3559-3568. DOI: https://doi.org/10.1038/onc.2012.362
Poirier JT, Gardner EE, Connis N, et al. DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2. Oncogene. 2015;34(48):5869-5878. DOI: https://doi.org/10.1038/onc.2015.38
Saito Y, Nagae G, Motoi N, et al. Prognostic significance of CpG island methylator phenotype in surgically resected small cell lung carcinoma. Cancer Science. 2016;107(3):320-325. DOI: https://doi.org/10.1111/cas.12876
Karlsson A, Jönsson M, Lauss M, et al. Genome-wide DNA methylation analysis of lung carcinoma reveals one neuroendocrine and four adenocarcinoma epitypes associated with patient outcome. Clinical Cancer Research. 2014;20(23):6127-6140. DOI: https://doi.org/10.1158/1078-0432.CCR-14-1087
Semenova EA, Nagel R, Berns A. Origins, genetic landscape, and emerging therapies of small cell lung cancer. Genes and Development. 2015;29(14):1447-62. DOI: https://doi.org/10.1101/gad.263145.115
Krushkal J, Silvers T, Reinhold WC, et al. Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets. Clinical Epigenetics. 2020;12:93. DOI: https://doi.org/10.1186/s13148-020-00876-8
Zhai G, Li J, Zheng J, et al. hTERT promoter methylation promotes small cell lung cancer progression and radiotherapy resistance. Journal of Radiation Research. 2020;61(5):674-683. DOI: https://doi.org/10.1093/jrr/rraa052
Mohammad HP, Smitheman KN, Kamat CD, et al. A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC. Cancer Cell. 2015;28(1):57-69. DOI: https://doi.org/10.1016/j.ccell.2015.06.002
Augert A, Eastwood E, Ibrahim AH, et al. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition. Science Signaling. 2019;12(567):eaau2922. DOI: https://doi.org/10.1126/scisignal.aau2922
Shi Y, Lan F, Matson C, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 2004;119(7):941-53. DOI: https://doi.org/10.1016/j.cell.2004.12.012
Khan P, Siddiqui JA, Maurya SK, et al. Epigenetic landscape of small cell lung cancer: small image of a giant recalcitrant disease. Seminars in Cancer Biology. 2022;83:57-76. DOI: https://doi.org/10.1016/j.semcancer.2020.11.006
Stewart CA, Byers LA. Altering the Course of Small Cell Lung Cancer: Targeting Cancer Stem Cells via LSD1 Inhibition. Cancer Cell. 2015;28(1):4-6. DOI: https://doi.org/10.1016/j.ccell.2015.06.011

All journals

Send article

Research Results in Biomedicine is included in the scientific database of the RINTs (license agreement No. 765-12/2014 dated 08.12.2014).

The journal is included in the list of peer-reviewed scientific publications recommended by the Higher Attestation Commission

The journal is indexed by the following scientific databases and platforms

Research Results in Biomedicine (ISSN 2658-6533)

The journal materials and website are licensed under Creative Commons «Attribution» 4.0 International.

The Founder: Federal State Autonomous Educational Institution of Higher Education "Belgorod National Research University"The Founder’s address: 85 Pobedy Street, Belgorod, the Belgorod region, 308015, Russia

The Publisher: Federal State Autonomous Educational Institution of HigherEducation "Belgorod National Research University" The Founder’s address:85 Pobedy Street, Belgorod, the Belgorod region, 308015, Russia

Editors Office: chief editor Mikhail I. Churnosov, e-mail: RR_MedPharm@bsu.edu.ru, phone: +7 (4722) 30-14-03.

Regulations on the Journal

Certificate

Have questions?
You can write to us:

✉ Content manager

✉ Site administration

✉ Executive Secretary